Chronic Cutaneous Ulcer and Burn Wounds -- Developing Products for Treatment
The purpose of this guidance is to provide recommendations to sponsors for the development of drugs, biological products, and devices2 to treat chronic cutaneous ulcer and burn wounds (i.e., wound-treatment products). The first part of this guidance addresses specific preclinical considerations. The guidance then addresses important considerations in clinical study design, including endpoint selection and manufacturing.
Submit comments on this guidance document electronically via docket ID: FDA-2013-S-0610 - Specific Electronic Submissions Intended For FDA's Dockets Management Staff (i.e., Citizen Petitions, Draft Proposed Guidance Documents, Variances, and other administrative record submissions)
If unable to submit comments online, please mail written comments to:
Division of Dockets Management (HFA- 305)
Food and Drug Administration
5630 Fishers Lane, Rm. 1061
Rockville, MD 20852
All comments should be identified with the title of the guidance.